Floatz logo

APAMISTAMAB-B10-ASTATINE AT-211

Recurrent Mixed Phenotype Acute Leukemia

Fred Hutchinson Cancer Centerantibody_drug_conjugatePhase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Recurrent Mixed Phenotype Acute Leukemia cohort.

Asset / SponsorPhaseRating
Daunorubicin
St. Jude Children's Research Hospital
Phase 4BB
METHOTREXATE
Children's Oncology Group
Phase 4BB
ETOPOSIDE
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3BB
Cytosin-Arabinosid
Children's Oncology Group
Phase 4BB
DEXAMETHASONE
St. Jude Children's Research Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

APAMISTAMAB-B10-ASTATINE AT-211 is also rated in:

acute lymphoblastic leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
myelodysplastic syndrome with excess blastsDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →